VASOACTIVE-INTESTINAL-PEPTIDE (VIP) MODULATES THE GROWTH FRACTION OF EPITHELIAL SKIN CELLS

被引:0
|
作者
WOLLINA, U [1 ]
BONNEKOH, B [1 ]
MAHRLE, G [1 ]
机构
[1] UNIV COLOGNE,W-5000 COLOGNE 41,GERMANY
关键词
EPITHELIAL CELL CULTURE; VASOACTIVE INTESTINAL PEPTIDE; KI67; ANTIGEN; HACAT CELL LINE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Using the human keratinocyte cell line HaCaT, modifications of the growth fraction due to vasoactive intestinal peptide (VIP) were determined by immunostaining with monoclonal antibody Ki67. In addition, the expression of VIP receptor and epidermal growth factor (EGF) receptor have been analysed. VIP (10-(7) to 10-(11) M) produced an almost doubling of the total number of Ki67-positive cells in cultures with 2% fetal calf serum (FCS), wheras it was ineffective in FCS-free and 10% FCS cultures. The nuclear Ki67-staining patterns were classified into four categories. In FCS-free cultures VIP induced a shift from type III (light nucleus, staining nuclei) to type II (multiple, intensely stained spots). In cultures with 2% FCS, VIP induced a shift from type II to type III. VIP receptor expression was facilitated by VIP, when cells were grown in a medium supplemented with 10% FCS. VIP increased EGF receptor expression in FCS-free cultures but decreased the number EGF receptor-positive cells in experiments with 2% FCS. In conclusion, VIP is capable to modulate the growth fraction and receptor expression of HaCaT cells in vitro. The effects are dependent on the concentration of FCS within the culture medium. The findings might be of interest for keratinocyte pathology in general and dermatooncology in particular.
引用
收藏
页码:17 / 24
页数:8
相关论文
共 50 条
  • [31] VASOACTIVE-INTESTINAL-PEPTIDE (VIP) AND RELATED PEPTIDES AS ANTIASTHMA AND ANTIINFLAMMATORY AGENTS
    SAID, SI
    BIOMEDICAL RESEARCH-TOKYO, 1992, 13 : 257 - 262
  • [32] BINDING OF VASOACTIVE-INTESTINAL-PEPTIDE (VIP) TO SUBSETS OF HUMAN CIRCULATING LYMPHOCYTES
    LAY, TE
    GREENBERG, GR
    OTTAWAY, CA
    GASTROENTEROLOGY, 1987, 92 (05) : 1495 - 1495
  • [33] VASOACTIVE-INTESTINAL-PEPTIDE (VIP) PROTECTS THE LUNG AGAINST OXIDANT INJURY
    BERISHA, H
    FODA, HD
    PAKBAZ, H
    SHARAF, H
    TROTZ, M
    SAID, SI
    CIRCULATION, 1992, 86 (04) : 354 - 354
  • [34] SEQUENCE OF A CDNA-ENCODING CHICKEN VASOACTIVE-INTESTINAL-PEPTIDE (VIP)
    MCFARLIN, DR
    LEHN, DA
    MORAN, SM
    MCDONALD, MJ
    EPSTEIN, ML
    GENE, 1995, 154 (02) : 211 - 213
  • [35] AUTOCRINE REGULATORY EFFECT OF VASOACTIVE-INTESTINAL-PEPTIDE (VIP) ON HUMAN PANCREATIC-CARCINOMA CELLS
    CHEN, Q
    CHEN, YF
    SHENG, HM
    HOU, X
    LU, GJ
    LUO, W
    PAN, GZ
    ZHONG, SX
    BIOMEDICAL RESEARCH-TOKYO, 1992, 13 : 225 - 225
  • [36] VASOACTIVE-INTESTINAL-PEPTIDE (VIP) RECEPTOR IMAGING IN THE LOCALIZATION OF INTESTINAL ADENOCARCINOMAS AND ENDOCRINE TUMORS
    VIRGOLINI, I
    RADERER, M
    ANGELBERGER, P
    BANYAI, S
    SCHEITHAUER, W
    VALENT, P
    JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (05) : P97 - P97
  • [37] COSECRETION OF PEPTIDE HISTIDINE METHIONINE (PHM) AND VASOACTIVE-INTESTINAL-PEPTIDE (VIP) IN PATIENTS WITH VIP-PRODUCING TUMORS
    FAHRENKRUG, J
    PEDERSEN, JH
    PEPTIDES, 1986, 7 (05) : 717 - 721
  • [38] EVIDENCE FOR VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTORS ON INTESTINAL EPITHELIAL-CELLS FROM RAT
    LABURTHE, M
    PRIETO, J
    DUPONT, C
    AMIRANOFF, B
    HUIBONHOA, D
    ROSSELIN, G
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1978, 13 : 106 - 106
  • [39] VASOACTIVE-INTESTINAL-PEPTIDE - A CHRONOIMMUNOMODULATOR
    GUGINI, P
    LUCIA, P
    DIPALMA, L
    POZZILLI, P
    RE, M
    CANOVA, R
    GASBARRONE, L
    CIANETTI, A
    BIOCHEMICAL MEDICINE AND METABOLIC BIOLOGY, 1991, 46 (02): : 274 - 276
  • [40] EFFECTS OF VASOACTIVE-INTESTINAL-PEPTIDE (VIP) ON SCOPOLAMINE-INDUCED AMNESIA IN THE RAT
    YAMAGUCHI, Y
    KOBAYASHI, H
    NEUROPEPTIDES, 1994, 26 (03) : 153 - 158